| Followers | 425 |
| Posts | 20207 |
| Boards Moderated | 1 |
| Alias Born | 02/22/2010 |
Monday, September 29, 2014 9:58:16 PM
$MSTX(.56) Target 1.20 by Piper Jaffray
Analyst Edward Tenthoff lifted his price target on Overweight-rated Mast Therapeutics (NYSE: MSTX) to $1.20 (from $1.00)
"Mast Therapeutics' MST-188 is currently enrolling the 388-patient Phase III EPIC trial to shorten vaso-occlusive crisis (VOC)," Tenthoff notes. Also highlighted:
Phase III EPIC Trial Enrollment On Track
Phase II ALI Study Underway.
MST-188 Heart Failure Potential.
Encouraging Phase II AIR001 PAH Data
Any thoughts here $SHEFF (good or bad) The entry here seems enticing... Might have to "Block Out All The Noise" :)
Analyst Edward Tenthoff lifted his price target on Overweight-rated Mast Therapeutics (NYSE: MSTX) to $1.20 (from $1.00)
"Mast Therapeutics' MST-188 is currently enrolling the 388-patient Phase III EPIC trial to shorten vaso-occlusive crisis (VOC)," Tenthoff notes. Also highlighted:
Phase III EPIC Trial Enrollment On Track
Phase II ALI Study Underway.
MST-188 Heart Failure Potential.
Encouraging Phase II AIR001 PAH Data
Any thoughts here $SHEFF (good or bad) The entry here seems enticing... Might have to "Block Out All The Noise" :)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
